Did clinical trials in which erythropoietin failed to reduce acute myocardial infarct size miss a narrow therapeutic window?
MI Talan, I Ahmet, EG Lakatta - PLoS One, 2012 - journals.plos.org
Background To test a hypothesis that in negative clinical trials of erythropoietin in patients
with acute myocardial infarction (MI) the erythropoietin (rhEPO) could be administered …
with acute myocardial infarction (MI) the erythropoietin (rhEPO) could be administered …
Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: dose response and therapeutic window
C Moon, M Krawczyk, D Paik, EG Lakatta… - … drugs and therapy, 2005 - Springer
Background: Recombinant human erythropoietin (rhEPO) protects tissue from ischemic
damage, but translation of this finding into useful guidelines with respect to human trials for …
damage, but translation of this finding into useful guidelines with respect to human trials for …
What is the role of erythropoietin in acute myocardial infarct? Bridging the gap between experimental models and clinical trials
F Roubille, F Prunier, S Barrère-Lemaire… - … drugs and therapy, 2013 - Springer
Erythropoietin (EPO) is the main hormone that regulates erythropoiesis. Beyond its well-
known hematopoietic action, EPO has diverse cellular effects in non-hematopoietic tissues …
known hematopoietic action, EPO has diverse cellular effects in non-hematopoietic tissues …
Erythropoietin treatment in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials
D Gao, N Ning, X Niu, Y Dang, X Dong, J Wei… - American Heart …, 2012 - Elsevier
BACKGROUND: In experimental models of acute myocardial infarction (AMI), erythropoietin
(EPO) reduces infarct size and improves left ventricular (LV) function. However, in the …
(EPO) reduces infarct size and improves left ventricular (LV) function. However, in the …
Failure of erythropoietin to render jeopardized ischemic myocardium amenable to incremental salvage by early reperfusion
CJ French, AKMT Zaman, BE Sobel - Coronary Artery Disease, 2009 - journals.lww.com
Objectives Erythropoietin (EPO) has been thought to be capable of potentiating protection of
jeopardized myocardium by reperfusion in evolving myocardial infarction. However, diversity …
jeopardized myocardium by reperfusion in evolving myocardial infarction. However, diversity …
Effects of erythropoietin after an acute myocardial infarction: rationale and study design of a prospective, randomized, clinical trial (HEBE III)
BACKGROUND: Preclinical studies have consistently shown that erythropoietin (EPO),
administered after an acute myocardial infarction (AMI), reduces infarct size and improves …
administered after an acute myocardial infarction (AMI), reduces infarct size and improves …
Therapeutic effectiveness of a single vs multiple doses of erythropoietin after experimental myocardial infarction in rats
C Moon, M Krawczyk, EG Lakatta, MI Talan - Cardiovascular drugs and …, 2006 - Springer
Background Systemic application of recombinant human erythropoietin (rhEPO) greatly
limits cardiac tissue damage and attenuates left ventricular (LV) remodeling after …
limits cardiac tissue damage and attenuates left ventricular (LV) remodeling after …
A single-center prospective randomized controlled trial evaluating the safety and efficacy of IntraCoronary Erythropoietin delivery BEfore Reperfusion: Gauging infarct …
BACKGROUND: Erythropoietin (EPO) protected the myocardium from ischemia and
reperfusion injury in preclinical studies. However, whether EPO can reduce myocardial …
reperfusion injury in preclinical studies. However, whether EPO can reduce myocardial …
Effect of erythropoietin as an adjunct to primary percutaneous coronary intervention: a randomised controlled clinical trial
Objective The acute administration of high-dose erythropoietin (EPO) on reperfusing
ischaemic myocardium has been reported to halve myocardial infarct (MI) size in preclinical …
ischaemic myocardium has been reported to halve myocardial infarct (MI) size in preclinical …
Single high-dose erythropoietin administration immediately after reperfusion in patients with ST-segment elevation myocardial infarction: results of the erythropoietin in …
F Prunier, L Bière, M Gilard, J Boschat, F Mouquet… - American Heart …, 2012 - Elsevier
BACKGROUND: Preclinical studies and pilot clinical trials have shown that high-dose
erythropoietin (EPO) reduces infarct size in acute myocardial infarction. We investigated …
erythropoietin (EPO) reduces infarct size in acute myocardial infarction. We investigated …